
Fifty1 AI Labs provides an AI-powered platform to repurpose approved medicines for new indications. It uses multimodal biomedical data and machine learning to connect disease biology to mechanism of action. The platform supports preclinical candidate selection, study design, and discovery partnerships for pharma and biotech customers. It integrates clinical data, chemical models, and regulatory insights to prioritize hypotheses and enable licensing or co-development. Fifty1 AI Labs focuses on off-patent compounds and antiviral programs, aiming to expand indications across therapeutic areas.

Fifty1 AI Labs provides an AI-powered platform to repurpose approved medicines for new indications. It uses multimodal biomedical data and machine learning to connect disease biology to mechanism of action. The platform supports preclinical candidate selection, study design, and discovery partnerships for pharma and biotech customers. It integrates clinical data, chemical models, and regulatory insights to prioritize hypotheses and enable licensing or co-development. Fifty1 AI Labs focuses on off-patent compounds and antiviral programs, aiming to expand indications across therapeutic areas.